Bachem
  • Products & Services
    • CMC Development
      • Peptide NCES
      • Oligonucleotide NCEs
    • Commercial APIs
      • Commercial NCEs
      • Commercial Generics
    • Research & Specialties
      • Catalog Peptides
      • Custom Peptide Synthesis
      • Amino Acid Derivatives
      • Diagnostics
      • Cosmetic Peptides
    • Services & Capabilities
      • Project Management
      • Quality & Regulatory
      • Analytical capabilities
      • GMP Production
      • Research Grade Production
      • Supply & vertical integration
  • About Bachem
    • Company overview
      • Our Purpose
      • Our vision & strategy
      • Our Leadership
      • Our History
      • Our Locations
    • Innovation
      • Innovation matters
      • Innovation collaborations
    • Sustainability
      • People & culture
      • Safeguarding the environment
      • Acting ethically
    • Investors & Media
      • Reports & Presentations
      • Financial events
      • Media Library
      • Press archive
  • News & Events
    • News
    • Events
  • Careers
  • Contact
Select Page
Fiscal Year 2019 – Record year points to increasing growth dynamics

Fiscal Year 2019 – Record year points to increasing growth dynamics

by Nikos Koukidis | Mar 13, 2020 | Finance, News, Press

Sales pass 300-million mark for the first time at 313.7 million CHF EBIT margin rises to 19.9%, EBITDA margin to 27.8% Net income up sharply to 54.2 million CHF Initial successes in oligonucleotide market Growth targets raised thanks to rising demand Proposed dividend...
Knowledge Center
General Conditions
Legal Statement
Privacy Policy
Imprint
Contact
  •  

  •  

  •  

  •  

  •